問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Thoracic Medicine

National Cheng Kung University Hospital Dou-Liou Branch (在職)

Division of General Internal Medicine

更新時間：2023-09-19

葉裕民Yeh, Yu-Min
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

  • i5485111@gmail.com

Recruiting Trial

185Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

葉裕民

List

332Cases

2019-03-01 - 2022-12-31

Phase III

A Phase 3, double-blind, multicenter, placebo-controlled study of PledOx used on top of modified FOLFOX6 (5?FU/FA and Oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN) in patients with first-line metastatic colorectal cancer

  • Condition/Disease

    Prevent chemotherapy-induced peripheral neuropathy (CIPN)

  • Test Drug

    PledOx

Participate Sites
4Sites

Terminated3Sites

王照元
Kaohsiung Municipal Gangshan Hospital

未分科

2019-03-01 - 2021-12-31

Phase III

A Phase 3, double-blind, multicenter, placebo-controlled study of PledOx used on top of modified FOLFOX6 (5-FU/FA and Oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN) in the adjuvant treatment of patients with Stage III or high-risk Stage II colorectal cancer

  • Condition/Disease

    Prevention of chemotherapy induced peripheral neuropathy (CIPN) (chemotherapy induced peripheral neuropathy)

  • Test Drug

    PledOx

Participate Sites
4Sites

Terminated3Sites

王照元
Kaohsiung Municipal Gangshan Hospital

未分科

2019-05-01 - 2026-12-31

Phase I/II

A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 in Patients with Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    BA3011

Participate Sites
4Sites

Recruiting4Sites

2019-09-01 - 2024-12-31

Phase I/II

A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 in Patients With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    BA3021

Participate Sites
4Sites

Recruiting4Sites

2021-05-01 - 2024-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2021-04-01 - 2024-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-12-01 - 2024-10-01

Phase I

A Phase 1/2, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors With KRasG12C Mutation

  • Condition/Disease

    Advanced or Metastatic Solid Tumors With KRasG12C Mutation

  • Test Drug

    D-1553

Participate Sites
4Sites

Recruiting4Sites

2021-01-15 - 2028-12-31

Phase I/II

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)

  • Condition/Disease

    Non-Small-Cell Lung

  • Test Drug

    Tecentriq Avastin Docetaxel Accord Ipatasertib Trajenta Sacituzumab Govitecan

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2022-07-06 - 2025-05-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2019-04-01 - 2022-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting1Sites

Terminated7Sites

1 21 22 23 24 25 34
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB